Vanqua Bio to Present at Inaugural GBA1 2024 Meeting
June 20 2024 - 7:30AM
Vanqua Bio, a biopharmaceutical company dedicated
to discovering and developing next-generation medicines for the
treatment of neurodegenerative diseases, announced today that it
will participate in the inaugural GBA1 meeting which will bring
together health professionals and stakeholders from both academia
and industry engaged in GBA1 research. The meeting will take place
from June 27 - 29, 2024, at The Montreal Neurological
Institute-Hospital. It is sponsored by Cure Parkinson’s, The
Michael J. Fox Foundation, Parkinson Canada, The Silverstein
Foundation, and the Hilary & Galen Weston Foundation.
The GBA1 meeting aims to advance the collective understanding
and treatment of GBA1-associated neurodegenerative diseases. Topics
of discussion will include all aspects of GBA1 research, from basic
science to clinical trials, offering a platform for networking,
learning, and collaboration.
Vanqua Bio Poster Presentation Information:
Title: VQ-101, A Small Molecule Allosteric Activator of
Glucocerebrosidase, Demonstrates Neuroprotection in Models of
GBA-Parkinson’s Disease and Robust in Vivo Target
EngagementPresenter: Daniel YsselsteinDate and time: June 29th
12:20 PM ET
About Vanqua BioFounded in 2019 and
headquartered in Chicago, Vanqua Bio is a biopharmaceutical company
dedicated to discovering and developing next-generation medicines
that have the potential to transform the lives of patients with
neurodegenerative diseases. Our technology platform utilizes human
genetics and patient-derived neuronal cells to identify, validate,
and clinically translate novel disease pathways associated with
lysosomal dysfunction or aberrant activation of the innate immune
system. Initially, we are targeting glucocerebrosidase (GCase) as a
potential treatment for Parkinson’s disease (PD). Additional
programs address overactivation of the innate immune system in
central and peripheral neurodegenerative disorders, including
Alzheimer’s disease. For more information, go
to www.vanquabio.com.
Media ContactAlyssa PaldoFINN
Partnersalyssa.paldo@finnpartners.com